

Exhibit 17

Note: Result is presented for the active ingredient, often including more than one brand name

Acetaminophen is an active ingredient

There are **179 436** reports with this active ingredient

Reported potential side effects

- › Blood and lymphatic system disorders (1%, 4 269 ADRs)
- › Cardiac disorders (2%, 5 265 ADRs)
- › Congenital, familial and genetic disorders (0%, 491 ADRs)
- › Ear and labyrinth disorders (0%, 1 011 ADRs)
- › Endocrine disorders (0%, 136 ADRs)
- › Eye disorders (3%, 9 415 ADRs)
- › Gastrointestinal disorders (10%, 28 446 ADRs)
- ▼ General disorders and administration site conditions (13%, 37 891 ADRs)
 - Drug ineffective (10 681)
 - Death (4 001)
 - Face oedema (2 766)
 - Pyrexia (2 607)
 - Pain (1 709)
 - Malaise (1 680)
 - Fatigue (1 512)
 - Therapeutic product effect incomplete (1 209)
 - Asthenia (1 161)
 - Oedema (946)
 - Drug interaction (867)
 - Therapeutic response unexpected (826)
 - Swelling (730)
 - Chest pain (712)
 - Swelling face (696)
 - Feeling abnormal (684)
 - Chills (670)
 - Condition aggravated (644)
 - Oedema peripheral (603)
 - Chest discomfort (501)
 - Drug ineffective for unapproved indication (481)
 - Therapeutic response decreased (479)
 - Multiple organ dysfunction syndrome (384)
 - Unevaluable event (383)
 - Hypothermia (368)
 - No adverse event (346)
 - Adverse event (317)
 - Peripheral swelling (312)
 - Feeling hot (298)
 - Gait disturbance (262)

VigiAccess


Crying (204)
 Infusion site pain (193)
 Adverse drug reaction (179)
 Therapeutic product effect decreased (178)
 Drug intolerance (174)
 Influenza like illness (167)
 Illness (165)
 General physical health deterioration (160)
 Discomfort (144)
 Drug withdrawal syndrome (144)
 Localised oedema (130)
 Feeling cold (110)
 Inflammation (104)
 Therapeutic product effect delayed (95)
 Gait inability (85)
 Therapy non-responder (79)
 Brain death (76)
 Thirst (76)

[Load more...](#)

- › Hepatobiliary disorders (5%, 14 101 ADRs)
- › Immune system disorders (2%, 5 936 ADRs)
- › Infections and infestations (1%, 3 892 ADRs)
- › Injury, poisoning and procedural complications (14%, 41 292 ADRs)
- › Investigations (4%, 12 321 ADRs)
- › Metabolism and nutrition disorders (1%, 3 986 ADRs)
- › Musculoskeletal and connective tissue disorders (1%, 3 509 ADRs)
- › Neoplasms benign, malignant and unspecified (incl cysts and polyps) (0%, 386 ADRs)
- › Nervous system disorders (7%, 19 063 ADRs)
- › Pregnancy, puerperium and perinatal conditions (0%, 820 ADRs)
- › Product issues (1%, 4 279 ADRs)
- › Psychiatric disorders (6%, 16 591 ADRs)
- › Renal and urinary disorders (2%, 4 639 ADRs)
- › Reproductive system and breast disorders (0%, 568 ADRs)
- › Respiratory, thoracic and mediastinal disorders (4%, 10 186 ADRs)
- › Skin and subcutaneous tissue disorders (18%, 51 290 ADRs)
- › Social circumstances (0%, 554 ADRs)
- › Surgical and medical procedures (0%, 765 ADRs)
- › Vascular disorders (2%, 5 438 ADRs)


Geographical distribution

[Chart](#) [Table](#)



Patient sex distribution

[Chart](#) [Table](#)




VigiAccess

Age group distribution

Chart


Table



ADR reports per year

Chart

Table



VigiAccess



VigiAccess is developed and maintained by the WHO Collaborating Centre for International Drug Monitoring, Uppsala Monitoring Centre on behalf of WHO